Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs L3Harris Technologies Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $302.38 (market cap $39.89B), while L3Harris Technologies Inc trades at $291.7 (market cap $54.17B). The key difference: L3Harris Technologies Inc is the larger of the two by market cap, and L3Harris Technologies Inc pays a 1.72% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | LHX | |
|---|---|---|
Market Cap | $39.89B | $54.17B |
Sector | Health | Industrials |
52-Week High | $491.22 | $378.48 |
52-Week Low | $278.09 | $259.55 |
Enterprise Value | $38.15B | $64.94B |
Dividend Yield | — | 1.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
LHX trades at $290.77, up 0.31% today, with a bearish technical signal but strong fundamentals. The company reported Q1 2026 EPS of $2.72, beating estimates, and maintains a 7.71% net income margin. Recent news includes a $84 million U.S. Army contract for NGC2 manpack systems (Business Wire, July 9, 2026). Cash flow from operations improved to $3.11B in 2025, while debt-to-asset ratio declined to 26.98%.
Outlook is positive with a consensus price target of $367.50, implying 26% upside, supported by 75% analyst buy ratings. Risks include execution delays in defense contracts and macroeconomic pressures. The stock offers value through earnings growth and dividend yield, but investors should monitor debt levels and competitive threats from new entrants like SpaceX.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
